thalidomide has been researched along with Carcinoma, Ductal, Breast in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Carcinoma, Ductal, Breast: An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martínez-Aranda, A | 1 |
| Hernández, V | 1 |
| Guney, E | 1 |
| Muixí, L | 1 |
| Foj, R | 1 |
| Baixeras, N | 1 |
| Cuadras, D | 1 |
| Moreno, V | 1 |
| Urruticoechea, A | 1 |
| Gil, M | 1 |
| Oliva, B | 1 |
| Moreno, F | 1 |
| González-Suarez, E | 1 |
| Vidal, N | 1 |
| Andreu, X | 1 |
| Seguí, MA | 1 |
| Ballester, R | 1 |
| Castella, E | 1 |
| Sierra, A | 1 |
| Shenoy, SK | 1 |
| Han, S | 1 |
| Zhao, YL | 1 |
| Hara, MR | 1 |
| Oliver, T | 1 |
| Cao, Y | 1 |
| Dewhirst, MW | 1 |
2 other studies available for thalidomide and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Area Under Curve; Astrocytes; Biom | 2015 |
β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression.
Topics: Active Transport, Cell Nucleus; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; | 2012 |